

Patient: **SAMPLE**
PATIENT

DOB: November 25, 1962

Sex: F

MRN:

Order Number:

Completed: October 14, 2009

Received: October 9, 2009

Collected: October 8, 2009

Lipid Markers

Cholesterol			Particle Concentration & Size by NMR		
	Result	Reference Range		Result	Reference Range
LDL- Cholesterol	95	< 100 mg/dL	LDL-Particle # (LDL-P)	1,050 H	< 1,000 nmol/L
HDL- Cholesterol	48 L	> 49 mg/dL	HDL-Particle # (HDL-P)	2.5 L	> 34.9 µmol/L *
Triglycerides	147	< 150 mg/dL	LDL-Size	Large (Pattern A) 23.0-20.6 * Small (Pattern B) 20.5-19.0 *	20.0
Total Cholesterol	158	< 200 mg/dL	Lp(a)	11	< 30 mg/dL

Independent Risk Factors

	Result	Reference Range		Relative Risk for Cardiovascular Disease
hs-CRP	0.89	< 1.00 mg/L	hs-CRP	
Lp-PLA ₂ (PLAC)	220 H	< 200 ng/mL	Lp-PLA ₂	
Fibrinogen	343	168-358 mg/dL	Fibrinogen	
Homocysteine	8.81	3.00 - 10.00 µmol/L	Homocysteine	

Insulin Resistance Score by Lipid Fractionation

Insulin Resistance Score:

HDL L	LDL s	VLDL L	HDL Size	LDL Size	VLDL Size
2.5	255	4.5	8.4	20.0	47.6
>7.3 µmol/L *	<117.0 nmol/L *	<0.9 nmol/L *	>9.6 nm *	>21.2 nm *	<42.4 nm *

The Insulin Resistance Score combines Small LDL-Particle #, LDL Size, Large VLDL-Particle #, VLDL Size, Large HDL-Particle # and HDL Size to assess insulin resistance and diabetes risk.

Optimal Borderline Abnormal

Percentiles Apply to Biomarkers indicated with * and are performed using NMR technology.

Optimal Either 0-25th or 75-100th percentile based on reference population.
 Borderline 25-75th Percentile
 Abnormal Inverse of Optimal (0-25th or 75-100th percentile distribution)

The LP(a), hs-CRP, Homocysteine, and Fibrinogen analytes have been approved by the U.S. Food and Drug Administration, and are performed by Genova Diagnostics, Inc. All other assays are performed by LipoScience, Inc. 2500 Sumner Blvd Raleigh, NC 27616